Natick medical device manufacturer Boston Scientific Corp. said today that the U.S. Food and Drug Administration has approved three products in its cardiac rhythm management business.
The FDA approved the Confient implantable cardioverter defibrillator, which protects patients at risk of sudden cardiac death; the Livian cardiac resynchronization therapy defibrillator, which combines cardiac resynchronization and defibrillation therapies in one device; and an upgraded Latitude patient management system.
The cardiac rhythm management products are designed to provide physicians with earlier insight into changing patient heart conditions, the company said.
